Analyst
Piper Jaffray
Equibles does not estimate personal net worth.
Ian Somaiya is recorded as Analyst at Piper Jaffray and CFO at NewAmsterdam Pharma Co N.V. (NAMS). The newest filing on record that lists Ian Somaiya as CFO at NewAmsterdam Pharma Co N.V. (NAMS) is dated May 6, 2026. The proxy statement of NewAmsterdam Pharma Co N.V. reports total compensation of $3,553,069 for Ian Somaiya in fiscal 2023, including a base salary of $90,576. Ian Somaiya has spoken on 1 investor event across 1 company, most recently for NewAmsterdam Pharma Co N.V. on May 13, 2026. NewAmsterdam Pharma Co N.V. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at NewAmsterdam Pharma Co N.V. includes Michael Davidson (CEO), Willian H. Lewis, J.D., M.B.A. (Chairman), Robert W. Gunning (Chief Accounting Officer) and 3 others.
“Obviously, we've shared a lot of data with you from our phase three studies for both of our lead programs, Obiseptrip, as well as the combination with azetamide.”
Piper Jaffray
Analyst
Source not stated
Start not stated–present
Last confirmed May 6, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | $90,576 | $3,553,069 |
